COPENHAGEN, Denmark, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on its Vision 3x3 strategic roadmap and planned 2023 key corporate milestones.
Expects High-Single-Digit Annual Net Revenue Growth and Annual Adjusted Operating Margin 1 Expansion of 50 to 150 Basis Points Through Fiscal 2030 Provides Planning Scenario of High-Single-Digit Net ...
Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven growth and innovation. Dublin, Ireland--(Newsfile Corp.
The new year marks the commencement of insightful dialogues surrounding emerging trends, innovative technologies, progressive business strategies and engaging interviews with esteemed industry leaders ...
MT. LAUREL, N.J.--(BUSINESS WIRE)--InTest Corporation (NYSE American: INTT), a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results